Spotlight Medical

Spotlight Medical develops AI-driven prognostic assays designed to help clinicians perform precise risk assessments for cancer patients. Their lead product, myStage Dx, analyzes routine H&E slides to provide actionable relapse scores for patients with node-positive, ER-positive, HER2-negative early-stage breast cancer. The technology combines standard baseline characteristics with tumor and microenvironment features to identify individuals who may have favorable outcomes despite high-risk clinical features.